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Background: IL-1 released from damaged endothelial cells (ECs) drives inflammation and chronic graft rejection. How
ECs activate IL-1 is unknown.
Results: Generation of active IL-1 in ECs requires caspase-1 proteolysis of an inhibitory complex that releases IL-1 and
enables calpain cleavage to the mature cytokine.
Conclusion: IL-1 is controlled post-translationally in ECs.
Significance:Multiple targets exist to prevent IL-1 activation during disease.
Inflammation is a key instigator of the immune responses that
drive atherosclerosis and allograft rejection. IL-1, a powerful
cytokine that activates both innate and adaptive immunity,
induces vessel inflammation after release fromnecrotic vascular
smooth muscle cells (VSMCs). Similarly, IL-1 released from
endothelial cells (ECs) damaged during transplant drives
allograft rejection. However, IL-1 requires cleavage for full
cytokine activity, and what controls cleavage in necrotic ECs is
currently unknown. We find that ECs have very low levels of
IL-1 activity upon necrosis. However, TNF or IL-1 induces
significant levels of active IL-1 in EC necrotic lysates without
alteration in protein levels. Increased activity requires cleavage
of IL-1 by calpain to themore activemature form. Immunofluo-
rescence and proximity ligation assays show that IL-1 associ-
ates with interleukin-1 receptor-2, and this association is
decreased by TNF or IL-1 and requires caspase activity. Thus,
TNF or IL-1 treatment of ECs leads to caspase proteolytic
activity that cleaves interleukin-1 receptor-2, allowing IL-1
dissociation and subsequent processingby calpain. Importantly,
ECs could be primed by IL-1 from adjacent damaged VSMCs,
and necrotic ECs could activate neighboring normal ECs and
VSMCs, causing them to release inflammatory cytokines and
up-regulate adhesionmolecules, thus amplifying inflammation.
These data unravel the molecular mechanisms and interplay
between damaged ECs and VSMCs that lead to activation of
IL-1 and, thus, initiation of adaptive responses that cause graft
rejection.
Chronic transplant allograft rejection is the leading cause of
late graft failure and mortality. Rejection is most commonly
caused by graft arteriosclerosis (chronic allograft vasculopa-
thy), which occurs due to a host immune alloresponse directed
against the graft blood vessels (1). Allograft vasculopathy is
characterized by progressive stenosis of vessels throughout the
organ due to deposition of extracellular matrix, VSMC2 prolif-
eration, and constrictive remodeling that occurs over months
to years. Vessel stenosis leads to ischemia, which is thought to
be the primary cause of parenchymal fibrosis within the tissue,
loss of function, and graft failure. Late graft failure occurs at a
rate of 5% per year post transplantation in the main solid organ
transplants (kidney, heart, liver) (1) and is currently untreat-
able. Graft ECs expressingMHCmolecules are amajor target of
this alloresponse, causing activation of CD4 memory T cells
and IFN production that is vital for arteriosclerosis (2). In
addition, other non-immune mechanisms also modulate the
development of arteriosclerosis.
Grafts are exposed to both physical and ischemic injuries
during the pre- and perioperative period. In particular, cadav-
eric donor grafts fail at accelerated rates, which may be due to
the greater injury they receive. The two main theories of why
injury drives graft failure are the “burden of injury hypothesis”
(3) and the “immune modulation hypothesis” (1). The former
postulates that grafts are exposed to multiple other injuries
such as periods of acute rejection, chronic rejection, and other
insults and can only tolerate a finite amount before the graft
fails. Thus, grafts exposed to more perioperative injury simply
exceed this limit earlier. The latter proposes that early graft
injury somehow alters a graft such that it interacts with the
host’s immune system in a way that accelerates rejection. The
two theories are likely linked, with graft damage driving cell
proliferation in the vesselwall as a typical response to injury and
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injured necrotic cells acting as a potent source of damage-asso-
ciated molecular patterns (DAMPs) that directly stimulate
innate and adaptive immune cells. DAMPs are typically mole-
cules that are exclusively intracellular under normal conditions
and, thus, their presence outside the cytosol indicates cell dam-
age and/or necrosis (4). Identified DAMPs include high-mobil-
ity group box 1, ATP, heat shock proteins, actin, uric acid,
DNA, and IL-1 (5). IL-1 is released from necrotic ECs and
is particularly important in graft rejection as it drives IL-17
and IFN production from infiltrating memory CD4 T cells
(6, 7), which are two cytokines of key significance in enhanced
alloimmunity.
IL-1 binds to the type 1 IL-1 receptor (IL-1R1) and recruits
IL-1 receptor accessory protein to form a complex that inter-
acts with the signaling adapter MyD88 (8). Following a phos-
pho-signaling cascade, NF-B is activated, inducing expression
ofmultiple proinflammatory genes (8). IL-1 is near universally
expressed and resides in the cytosol as a 33-kDa precursor that
is reported to be fully biologically active, and thus release from
damaged cells enables it to act as a universal danger signal or
“alarmin.” However, recent work has shown that pro-IL-1 has
far less cytokine activity than the calpain-cleaved mature form
and acts as a partial agonist due to low binding affinity for
IL-1R1 (9, 10). Furthermore IL-1 activity after necrosis is reg-
ulated in a cell type-specific manner with most cells unable to
cleave IL-1 upon necrosis and, therefore, contain no IL-1
activity (10). IL-1 released from damaged ECs drives the T
helper 17 cell (Th17) responses that induce vessel arterioscle-
rosis and subsequent allograft rejection (6, 7), suggesting that
ECs must be able to activate pro-IL-1. However, whether ECs
constitutively express IL-1, what causes cleavage and/or acti-
vation of IL-1 and the mechanism controlling this is not
known. We find that IL-1 activity is regulated via a novel
mechanism involving TNF- and IL-1-induced caspase activity
that cleaves IL-1R2, causing IL-1 dissociation that enabled
subsequent processing by calpain.
Experimental Procedures
Tissue Culture—All material was from Sigma unless stated
otherwise.Humanumbilical vein ECs (HUVECs)were cultured
in large vessel endothelial cell media with supplements (all TCS
Cellworks), human aortic VSMCs andHeLa cells were cultured
in DMEM, 10% FCS, 10 units/ml penicillin, 10 mg/ml strepto-
mycin, 5 mg/ml L-glutamine, and all were passaged at 80% con-
fluence. EL4 and THP1 cells were cultured in RPMI, 10% FCS,
10 units/ml penicillin, 10 mg/ml streptomycin, 5 mg/ml L-glu-
tamine, 2.3 M -mercaptoethanol and maintained between
4–10 105/ml.Where indicatedHUVEC cells were pretreated
for 16 h with IL-1 (10 ng/ml) or TNF (10 ng/ml; both Pepro-
tech) with and without benzyloxycarbonyl-VAD-fluoromethyl
ketone (100 M, Bachem) or benzyloxycarbonyl-YVAD-fluo-
romethyl ketone (20 M, BioVision). Necrotic lysates were
made by resuspending cells in serum-free DMEM with and
without calpeptin (30 M; Enzo) and freeze/thawing 3 times in
liquidN2 before removal of insolublematerial by centrifugation
(1  104 g; 3 min). Necrotic lysates were made at 1  105
(HUVECs), 15  104 (THP1 and HeLa), or 5  104 (VSMCs)
cells per 72l of serum-free DMEM.Western blot lysates were
made with 600,000 cells per 24 l of media. To detect IL-1-
specific activity, control VSMCs were adhered overnight and
then incubated in low serum (1%) media for 24 h, whereas
HeLa cells and HUVECs were only adhered overnight in full
media.Media were replaced along with treatments as indicated
and incubated for 6 h. EL4 cells were washed and plated in
serum-freemedia alongwith treatments and incubated for 24 h.
Conditioned media was collected and clarified, and cytokines
were assayed as below. Specific IL-1 activity was inferred with
a neutralizing antibody (2 g/ml; Peprotech) added during the
6-h incubation. HUVECs were transfected by nucleofection
(VPB-1002; program A034; Lonza). 250 103 cells were trans-
fected with wild type or mutant IL-1R2 or empty vector
(pcDNA 3.1; 2 g; Invitrogen) along with pmaxGFP (0.2 g;
Lonza) before electroporation. Cells were transferred into full
media and incubated for 2 days before use.
Cytokine Measurement—Clarified supernatants were ana-
lyzed by plate ELISA for IL-1 and IL-2 (both Peprotech), or
cytometric bead ELISA for IL-6, IL-8, andMCP-1 (eBioscience)
as per themanufacturer’s instructions. Plates weremeasured at
450 nm on a spectrophotometer (Gen5) with the data analyzed
using a 4-parameter logistic standard curve. Beads were mea-
sured by cytometry (Accuri C6), and data were analyzed with
FlowCytomix Pro (eBiosciences).
RT-PCR and Quantitative PCR—RNA was isolated using
TRIzol reagent and DNase-treated (Ambion) before reverse
transcription with MMLV and oligo(dT) (Promega). Quantita-
tive PCR used TaqMan probe/primers with AmpliTaq gold
(Life Technologies) in a RotorGene thermocycler (Corbett).
Analysis utilized standard curves with specific expression level
normalized to GUSB and TBP. IL-1R2 transcript was assessed
by RT-PCR using the primers: soluble IL-1R2 forward (TGGC-
ACCTACGTCTGCACTA) and reverse (TGTCTCCAAAAG-
GAAGAGCGA); membrane IL-1R2 forward (ACACGGATG-
TGGGCCCAGGA) and reverse (GTGAAAGTGGGGCCAG-
CACA);GAPDH forward (TGTTGCCATCAATGACCCCTT)
and reverse (CTCCACGACTGACTCAGCG).
Western Blotting—Western Blotting was performed as previ-
ously described with lysis of cells directly in Laemmli buffer,
SDS-PAGE, and transfer onto PVDFmembrane. After blocking
(5% milk), membranes were incubated (4 °C; 16 h) with IL-1
pAb (1:500; Peprotech), IL-1R2 pAb (1:250; R&D), or -actin
mAb (1:5000; Sigma) before washing (PBS/Tween) and incuba-
tion (room temperature for 1 h) with anti-rabbit HRP (1:2000;
GE Healthcare) or anti-goat HRP (1:2000; Jackson ImmunoRe-
search). After washing membranes were visualized with ECL
reagent (Amersham Biosciences) and x-ray film (Fujifilm).
IL-1R2 Protection Assay—Necrotic HUVEC lysates from
either control or IL-1-treated cells were incubated with
increasing amounts of His-tagged pro-IL-1 (0–250 ng) and
incubated (37 °C; 1 h) before the addition of 3Laemmli buffer,
boiling, and analysis by Western blotting.
Calpain Activity—Calpain activity was assayed using the
luminescent CalpainGlo kit (Promega). Test sample and re-
agents were mixed 50:50 and incubated (room temperature; 10
min) before analysis on a luminometer (Turner Biosystems).
Immunofluorescence and Proximity Ligation Assay—HUVECs
adhered to coverslips were treated as indicated before fixation
IL-1R2 Controls IL-1 Activity in Necrotic Endothelial Cells
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with formaldehyde (2%; room temperature; 15 min) and then
methanol (10 min; 20 °C) before washing (PBS). Cells were
blocked with BSA (1%; 1 h) before incubation (4 °C; 16 h) with
IL-1 pAb (1:100; Aviva) and IL-1R2 mAb (1:40; R&D) in a
humidified chamber. After washing (0.05% Tween, PBS), cov-
erslips were either stained with Duolink probes as per theman-
ufacturer’s instructions (OLink Bioscience) along with a probe-
only control or AlexaFluor goat anti-rabbit 488 (IL-1) and
goat anti-mouse 568 (IL-1R2) (both 1:500; 1 h) beforemounting
in ProLongGold (all Invitrogen). Imagingwas performedwith a
BX51 microscope (Olympus) with CellD imaging software
(SIS).
FlowCytometry—HUVECs in suspensionwere fixed in form-
aldehyde (2%; 10 min), washed (PBS) by centrifugation (220
g; 5min), resuspended intomethanol (20 °C; 10min), washed,
and blocked in BSA (1%; 1 h). Cells were incubated (30 min;
room temperature) with IL-1R2mAb (1:40; R&D) or IL-1 pAb
(1:100; Aviva), washed, and incubated with AlexaFluor goat
anti-rabbit 488 (IL-1) or goat anti-mouse 568 (IL-1R2) (both
1:500; 40 min). A matched isotype and secondary control was
performed for eachHUVEC condition and subtracted from the
mean fluorescent intensities values shown. Washed cells were
resuspended in 200 l of 1% BSA, PBS and analyzed by flow
cytometry. For intracellular staining, saponin (0.1%) was added
to buffers throughout to permeabilize cells, changing to 1%
BSA/PBS before analysis by flow cytometry.
Statistics—Data are presented as themean S.E. unless oth-
erwise stated. All assays that produced continuous data, with
the exception of flow cytometry, were performed in duplicate.
n an individual experimental replicate. Parametric tests were
employed for analysis of continuous data, conducted using a
one-way, two-tailed analysis of variance (Excel). Significance is
as stated, but always p  0.05. Non-significant data were con-
sidered anything where p	 0.05. All Westerns blots presented
are representative of three separate experiments.
Results
IL-1 Activity in Necrotic Endothelial Cells Is Controlled
Independently of Protein Level—IL-1 derived from injured
donor ECs is required for intimal T cell recruitment and IL-17
production in graft allopathy (6, 7), suggesting that ECsmust be
able to activate IL-1 upon necrosis. We first examined
necrotic HUVEC lysates for IL-1 activity using an EL4 cell
bioassay in which IL-2 is produced in an IL-1-dependent man-
ner. EL4 cells display very high sensitivity to IL-1, responding to
femtomolar concentrations. Treatment of EL4 cells with
necroticVSMC lysates as a positive control (10) resulted in high
levels of IL-2 production (8000 200 pg/ml) (Fig. 1A), which
was shown to be IL-1-dependentwith a neutralizing antibody.
However, necrotic HUVEC lysates induced minimal IL-2
release, similar to HeLa and THP1 necrotic lysates (300 25
pg/ml) (Fig. 1B). HeLa and THP-1 cells have previously been
shown to contain negligible IL-1 activity after necrosis (10),
suggesting that ECs are unable to activate IL-1 upon necrosis.
However, despite comparable levels of IL-1 activity between
the cell types, Western blot showed that HUVECs contain
10% of the IL-1 protein observed in THP1 and HeLa cells
(Fig. 1C). This indicates that IL-1 protein expression in
HUVEC necrotic lysates is not predictive of IL-1 activity, sug-
gesting that anothermechanism regulates IL-1 activity in ECs.
Due to the high sensitivity of the EL4 bioassay, IL-1 activity in
necroticHUVEC lysates was reassessed usingHeLa cells, which
release IL-6 more linearly in response to IL-1 (10). Necrotic
HUVEC lysates induced similar activity to the negative control
FIGURE 1. IL-1 activity in necrotic endothelial cells is controlled independently of protein level. A and B, IL-1-dependent IL-2 production by EL4 cells
incubatedwith necrotic VSMC lysates (A) or necrotic cell lysates as indicated (B) with andwithout neutralizing IL-1 antibody ( pAb). C, Western blot for IL-1
or -actin in whole cell lysates of cell-types indicated. D, IL-1-dependent IL-6 production by HeLa cells incubated with necrotic HUVEC lysates pretreated as
indicated with and without IL-1 pAb. Data represent the mean S.E. of n 3 (A and B) and5 (D). *, p 0.05; **, p 0.01; ***, p 0.001.
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(Fig. 1D). However, pretreatment of ECs with TNF or IL-1
before making necrotic lysates resulted in a large increase in
IL-1-specific activity. Together these data suggest that
unstimulated HUVECs contain minimal amounts of IL-1
activity but that this can be increased by activation of the cell
before necrosis.
Increased IL-1 Activity in Activated ECs Occurs Due to
IL-1Cleavage by Calpain—The increase in IL-1 activity seen
in necroticHUVECs after IL-1 orTNF treatment could be due
to increased IL-1 protein, increased IL-1 cleavage, or loss of
an IL-1 antagonist. We, therefore, examined IL-1 mRNA in
HUVECs treated with TNF or IL-1. Although activated
HUVECs had increased IL-1 transcripts compared with con-
trol cells (Fig. 2A), IL-1 protein levels were similar byWestern
blotting (Fig. 2B) or intracellular cytokine staining and flow
cytometry (Fig. 2C), confirming that IL-1 activity is not corre-
lated to IL-1 protein expression. Calpain cleavage of pro-
IL-1 during necrosis significantly increases activity. As
necrotic EC lysates contain calpain activity comparable with
other cell types that were not altered by TNF or IL-1 treat-
ment (Fig. 2D), we investigated whether EC activation resulted
in more IL-1 processing using a cleaved IL-1-specific ELISA
(Fig. 2, E and F). Pretreatment of ECs with TNF or IL-1
before necrosis significantly increased cleaved IL-1 compared
with control (Fig. 2G), which was inhibited by the calpain-spe-
cific inhibitor calpeptin (Fig. 2G). Thus, the increased IL-1
activity in necrotic EC lysates after activation is due to increased
IL-1 cleavage and not increased IL-1 protein.
IL-1 Binding to IL-1R2 Prevents Calpain Cleavage and Con-
trols Cytokine Activity in ECs—IL-1 activity can be regulated
by an intracellular form of IL-1R2 that protects pro-IL-1 from
calpain cleavage (10). HUVECs expressed transcripts for both
the membrane-bound and soluble forms of IL-1R2 (Fig. 3A),
whereas immunofluorescence revealed pro-IL-1 and IL-1R2
to be highly co-localized (Fig. 3B). Although co-localization by
immunofluorescence suggests association, it does not prove
binding.However, an in situ proximity ligation assay (DuoLink)
revealed that IL-1 and IL-1R2 are physically associated in con-
trol ECs (Fig. 3C). As IL-1R2 binding protects IL-1 from cal-
pain cleavage, a general reduction in the steady state level of
IL-1R2 protein could allow more processing and activation of
IL-1 upon necrosis. However, TNF or IL-1 treatment did
FIGURE2. Increased IL-1activity inactivatedECsoccursdue to IL-1 cleavagebycalpain.AandB. level of IL-1 transcript relative toGusBbyquantitative
PCR (A) or protein by Western blot in whole cell lysates of HUVECs pretreated as indicated. C, mean fluorescent intensities (MFI) of HUVEC cells, pretreated as
indicated, stained for IL-1, andanalyzedby flowcytometry.D, relative level of calpain activityusinga substrate assay innecrotic lysatesof the cell types treated
as indicated. E, ELISA analysis of recombinantmature (p17) and pro-IL-1 (p33) at the concentrations indicated (pg/ml) and endogenous IL-1within necrotic
VSMC lysates made with and without calpain inhibition (Ci). F, Western blot for IL-1 showing calpeptin (Ci) prevents processing of p33 to p17. G, mature
IL-1 (p17) content by ELISAof necrotic HUVEC lysates pretreated as indicated andmadewith andwithout calpain inhibition (Ci). Data represent themean
S.E. of n 2 (A and C), 3 (E), and 4 (F); *, p 0.05, **, p 0.01; NS not significant.
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not affect IL-1R2 protein levels onWestern blotting (Fig. 3D) or
flow cytometry (Fig. 3E).
EC Activation Reduces the Interaction between IL-1 and
IL-1R2—Most cell types have excess IL-1R2 that can protect
exogenously added pro-IL-1 from calpain cleavage. Thus,
by incubating necrotic EC lysates with increasing concentra-
tions of exogenous pro-IL-1 and measuring the amount of
uncleaved pro-IL-1, we can determine the amount of “com-
petent” IL-1R2. This showed that necrotic lysates from
HUVECs prestimulated with IL-1 were less able to protect
exogenous pro-IL-1 against cleavage compared with control
lysates (Fig. 4A). This supports that activated ECs have more
cleaved IL-1 (Fig. 2G) because IL-1R2 is less able to protect it
from calpain cleavage. To confirm this, IL-1/IL-1R2 associa-
tion was quantified with DuoLink, which visually showed
decreased association after TNF and IL-1 treatment (Fig.
4B). Blinded interaction counts per cell confirmed this decrease
(Fig. 4C), as did DuoLink performed in suspension quantified
by FACs (Fig. 4D). Together these data suggest that IL-1 activ-
ity increases in pretreated necrotic EC lysates due to a reduc-
tion in IL-1R2/IL-1 association that subsequently allows
IL-1 processing by calpain to the more active mature form.
Caspase-1 Cleavage of IL-1R2 Enables Induction of IL-1
Activity in Stimulated ECs—IL-1R2 cleavage by caspase-1 is
reported to cause its disassociation from pro-IL-1, which sub-
sequently enables calpain cleavage and activation (10). As no
significant change in IL-1R2 protein level was found (Fig. 3, D
and E), we postulated that caspase-1 cleavage of IL-1R2 could
be responsible for the decreased association with IL-1 seen
after EC stimulation. HUVECs were treated concurrently with
TNF and the pan-caspase inhibitor ZVAD-fluoromethyl
ketone or the caspase-1-specific inhibitor YVAD-fluoromethyl
ketone. Both inhibitors significantly reduced TNF-induced
IL-1 activity seen in necrotic lysates (Fig. 5A). Importantly, as
all TNF-induced IL-1 activity was IL-1-specific, this
excludes any effect of caspase inhibition on IL-1 activation. To
confirm that caspase action increased IL-1 activity by promot-
ing IL-1R2 cleavage, we expressed a form of IL-1R2 that cannot
be cleaved by caspase-1 due tomutation of the keyAsp residues
(10). Using nucleofection, a HUVEC transfection efficiency of
62% was achieved (Fig. 5B). Transfection of wild-type IL-1R2
had no effect on TNF-induced IL-1 activity (Fig. 5C). In con-
trast, expression of mutant IL-1R2 significantly reduced IL-1
activity (Fig. 5C). Importantly, transfection of an empty plasmid
FIGURE3. IL-1binding to IL-1R2prevents calpain cleavageand controls cytokineactivity in ECs.A, RT-PCR formembrane (mIL-1R2) and soluble (sIL-1R2)
IL-1R2andGAPDH transcriptwithin THP1andHUVECcells.B, dual immunofluorescence for pro-IL-1 and IL-1R2 in controlHUVECs. Scale bars represent 50m.
C, proximity ligation assay (DuoLink) showing association between IL-1 and IL-1R2 in control HUVEC cells. D, Western blot for IL-1R2 in whole cell lysates of
HUVECs pretreated as indicated. E, mean fluorescent intensity (MFI) minus isotype control of HUVEC cells, pretreated as indicated, stained for IL-1R2, and
analyzed by flow cytometry. Data represent the mean S.E. of n 2.
FIGURE 4. EC activation reduces the interaction between IL-1 and
IL-1R2. A, Western blot for IL-1 in necrotic HUVEC lysates, pretreated as
indicated, and incubated with increasing quantities of exogenous pro-IL-1
(p33). B, proximity ligation assay (DuoLink) showing association between
IL-1 and IL-1R2 in HUVEC cells pretreated as indicated. C and D, relative
number of interactions between IL-1 and IL-1R2 in HUVECs pretreated as
indicated, assessed by DuoLink and quantified by blinded counting (C) and
flow cytometry (D). MFI, mean fluorescent intensity. Data represent the
mean S.E. of n 2; *, p 0.05.
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neither induced nor inhibited TNF-induced IL-1 activity
(Fig. 5C). Together, these experiments strongly suggest that
cleavage of IL-1R2 by caspase-1 is an important step that
enables the subsequent activation of IL-1 in necrotic EC
lysates.
Necrotic EC Lysates Activate Adjacent Cells to a Proinflam-
matory State—Given that necrotic EC-derived IL-1 drives
graft rejection and that these data show that ECs need priming
to activate IL-1, we investigated the source of this initial stim-
ulus. TNF can be produced by ECs after IL-1, LPS, or TNF
treatment (11, 12). However, this requires time for transcrip-
tion, translation, processing, and secretion. In contrast, as
VSMCs can activate IL-1 upon necrosis without prior cyto-
kine activation (Ref. 10 and Fig. 1A) whereas multiple other cell
types can not (data not shown and Ref 10), we tested whether
VSMC necrotic lysates could prime ECs. Treatment of
HUVECs with necrotic VSMC lysates resulted in significant
increases in active IL-1 in necrotic EC lysates (Fig. 6A), which
was inhibited by neutralization of the VSMC-derived IL-1
during the priming step (Fig. 6A) or calpain inhibition during
preparation of the HUVEC necrotic lysate (Fig. 6A). This sug-
gests that VSMCs damaged during the perioperative period
could provide active IL-1 that can prime ECs. Similarly, we
tested whether necrotic EC lysates could activate adjacent ECs
and VSMCs. Treatment of VSMCs (Fig. 6B) or HUVECs (Fig.
6C) with necrotic HUVEC lysates led to significant release of
IL-6, IL-8, and MCP-1, which was dependent upon necrotic
EC-derived IL-1. In addition,HUVECs also showed IL-1-de-
pendent up-regulation of the cell surface adhesion molecules
E-selectin and intercellular adhesion molecule 1 (ICAM-1; Fig.
6, D–F). Together these data indicate that interplay between
damaged VSMCs and ECs could initiate activation of IL-1 in
ECs, which in turn can activate adjacent vessel wall cells to
effectively amplify inflammation.
Discussion
Immune system activation protects organisms from patho-
gens able to challenge host fitness, usually by detecting patho-
gen-associated molecular patterns that are recognized as non-
self by innate immune cells. However, immune activation also
occurs without infection as a vital means of dealing with phys-
ical insults such as trauma, burns, tissue anoxia, or cytotoxic
chemicals. This sterile inflammation is instigated by host-de-
rived factors known as damage-associated molecular patterns
that usually reside intracellularly but are released after cell
damage. Conversely, immune activation by these endogenous
factors also drives diseases such as arthritis, atherosclerosis,
and graft rejection.Although IL-1 released fromdamagedECs
drives immune responses that cause arteriosclerosis and graft
failure (6, 7), what controls IL-1 activity in ECs is unknown.
We find that unstimulated ECs constitutively express small
amounts of IL-1protein but that it has no activity upon release
from damaged cells. However, after prior activation with TNF
or IL-1, necrotic EC lysates show significantly increased IL-1
activity without any increase in IL-1 protein. Necrotic lysates
made from unstimulated ECs contain only pro-IL-1, whereas
stimulated necrotic EC lysates contain calpain-cleaved mature
IL-1, which ismuchmore active.UnstimulatedECshave cyto-
solic IL-1 that is co-localized and associated with IL-1R2,
which protects it from calpain cleavage and activation. Stimu-
lated ECs show reduced IL-1/IL-1R2 interaction due to
caspase cleavage of IL-1R2, which causes complex disassocia-
tion and enables calpain to cleave pro-IL-1. Unstimulated ECs
can be primed by damaged adjacent VSMCs that natively con-
tain active IL-1, whereas necrotic EC lysates from stimulated
cells cause cytokine release and adhesion receptor up-regula-
tion in adjacent viable VSMCs and ECs, thereby amplifying
inflammation (outlined in Fig. 7). Thus, interplay between
damaged ECs and other vessel wall cells leads to IL-1 activa-
tion that can drive subsequent Th17 responses and drive graft
rejection.
IL-1 is a likely candidate to drive graft failure, as it can both
induce inflammation and activate adaptive immunity. Indeed,
inhibition of IL-1 signaling with IL-1RA or sIL-1R1 promotes
survival in cardiac allografts (13), corneal grafts (14), and islet
cell transplants (15) and also reduces graft versus host disease
after bone marrow transplant (16). Furthermore, components
of the inflammasomes upstream of IL-1 activation also show
up-regulation during graft rejection (17). Although we cur-
rently do not understand how an intracellular form of IL-1R2 is
expressed, it is present inside multiple cell types (10) including
ECs. Using adenovirus-mediated transfer of sIL-1R2 to endo-
thelial cells within cardiac allografts, Simeoni et al. (18) found
decreased CD4 cell infiltration and significantly increased
graft survival, again supporting inhibition of IL-1 as a means of
preventing graft rejection. IL-1 signaling typically results in
production of IL-6, MCP-1, and IL-8. In particular, IL-1 and
FIGURE 5. Caspase-1 cleavage of IL-1R2 enables induction of IL-1 activ-
ity in stimulated ECs. A, IL-1-dependent IL-6 production by HeLa cells incu-
bated with and without IL-1 pAb with necrotic HUVEC lysates pretreated
with TNFwith and without caspase inhibitors. B, flow cytometric analysis of
HUVECs with and without transfection of a GFP expression plasmid. C, IL-1-
dependent IL-6 production by HeLa cells incubated with and without IL-1
pAb with necrotic HUVEC lysates from cells transfected with WT or mutant
IL-1R2 as indicated pretreated with and without TNF. Data represent the
mean S.E. of n 3; **, p 0.01. NS not significant.
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IL-6 strongly promote Th17 differentiation of T cells (19) and
the subsequent IL-17 production that drives rejection (20). Fur-
thermore, although MCP-1 is considered a classic chemokine
formonocytes, it is also a powerful T cell chomoattractant (21).
Indeed, Rao (7) reported significantly decreased T cell recruit-
ment and IL-17 production in vivo after IL-1 blockade during
vessel allograft rejection.
IL-1 is rarely found outside cells or in the circulation with-
out cell death and as such has been described as an Alarmin, i.e.
an endogenously derived DAMP. Although still contested (22),
we and others find that IL-1 requires cleavage for full activity,
with the proform showing low receptor affinity (9, 10).
Although EC-derived IL-1 drives allograft rejection, our data
show that IL-1 is uncleaved and inactive in unstimulated ECs
due to its associationwith IL-1R2. ECs need an initial “insult” to
generate active IL-1 such as pretreatment with TNF or IL-1,
which leads to the caspase-dependent release of IL-1R2 from
pro-IL-1. Caspase-1 is normally activated by the supramo-
lecular inflammasomes that typically require an initial signal
through Toll-like receptors (e.g. LPS) followed by a second
stimulus (e.g. ATP, crystalline material) that leads to caspase-1
activation (23). However, some cell types only require the first
toll-like receptor signal to activate caspase-1 (e.g. monocytes)
(24). Therefore, as IL-1R1 and toll-like receptors share the same
TIR domain and signaling pathway, IL-1 stimulation function-
ally equates to toll-like receptor ligation and thus could lead to
caspase-1 activation in ECs. Two independent lines of evidence
support the involvement of caspase-1 in this process; first, use
of either a pan- or caspase-1-specific inhibitor reduces IL-1
activation after necrosis; second, expression of IL-1R2 with a
mutation in the specific caspase-1 cleavage site acts as a domi-
nant negative in ECs, resulting in less activation of IL-1 after
necrosis. Interestingly, despite activation of caspase-1, we see
no evidence of IL-1 activity in necrotic EC lysates, suggesting
that ECs either do not express pro-IL-1 or that it is compart-
mentalized away from the caspase-1 activity.
These and previous data (6, 7) also suggest that the burden of
injury hypothesis (3) and the immune modulation hypothesis
(1) of graft rejection cannot bemutually exclusive.Necrotic ECs
cannot activate IL-1 without initial damage to vessels that
cause release of active IL-1 from VSMCs or other sources,
However, once primed, ECs can subsequently activate IL-1
FIGURE 6. Necrotic EC lysates activate adjacent cells to a proinflammatory state. A, IL-1 activity within necrotic HUVEC lysates pretreated with and
without calpeptin necrotic VSMC lysates, with and without IL-1 pAb during the priming step, or with and without calpeptin (Ci) during preparation of the
necrotic HUVEC lysate. B andC, cytokine content of conditionedmedia fromcontrol VSMCs (B) or HUVECs (C) with andwithout calpeptinpAb incubatedwith
necrotic HUVEC lysates pretreated with and without calpeptin TNF. Note the MCP-1 values in C plotted at 50%. D, FACs plots show that IL-1-dependent
increase in surface E-selectin expression after treatment with necrotic HUVEC lysates pretreated with and without TNF. E and F, mean fluorescent intensities
(MFI) of HUVEC populations stained for intercellular adhesion molecule 1 (ICAM-1; E) or E-selectin (F) analyzed by FACs after treatment as indicated with and
without calpeptin  pAb. Data represent the mean S.D. of n 3 (A–C) and 2 (D–F); **, p 0.01; ***, p 0.001. NS not significant.
IL-1R2 Controls IL-1 Activity in Necrotic Endothelial Cells
25194 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 41•OCTOBER 9, 2015
 at Cam
bridge U
niversity Library on N
ovem
ber 24, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
upon necrosis and in addition up-regulate adhesion molecules
such as intercellular adhesion molecule 1 and E-selectin, lead-
ing to recruitment of leukocytes. Within this milieu of IL-1-
and IL-1-induced cytokinesCD4memoryT cells will be pushed
toward the Th17 lineage with production of IL-17 and instigate
arteriosclerosis and graft rejection. Thismodulation of adaptive
immunity can cause destruction of vascular wall cells and acute
rejection. However, although effective immunosuppression
prevents this acute response, chronic rejection still occurs, with
progressive stenosis due to neointimal expansion causing tissue
ischemia. Innumerous factors have been described to cause
VSMC migration and proliferation in multiple models of
neointima formation; however, what growth factors or cyto-
kines cause this during graft arteriosclerosis is poorly under-
stood. Interestingly, as the pathological changes remain con-
fined to the donor tissue (literally stopping at the suture lines)
and do not affect the host vasculature (25), this suggests that
neointimal formation is dependent on cell-cell interactions
rather than soluble mitogenic factors.
In conclusion, our data show that although EC-derived IL-1
is key in driving graft arteriosclerosis, it is inactive in unstimu-
lated ECs due to binding to IL-1R2. ECs need priming via IL-1
derived from damaged VSMCs or TNF to enable IL-1 acti-
vation upon necrosis, which leads to caspase-1-mediated cleav-
age of IL-1R2 and complex disassociation. In addition, necrotic
EC-derived IL-1 causes inflammatory cytokine production
and adhesion molecular up-regulation by adjacent ECs and
VSMCs. These data help clarify the complex interplay between
cell types in perioperatively damaged vessels that lead to IL-1-
driven adaptive immunity and subsequent rejection. In addi-
tion, these data suggest that inhibition of inflammasomes,
caspase-1, calpain, or IL-1 are potential therapeutic candi-
dates to prevent arteriosclerosis and allograft rejection.
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